Abstract Purpose: ABT-888, currently in phase 2 trials, is a potent oral poly (ADP-ribose)
polymerase inhibitor that enhances the activity of multiple DNA-damaging agents, including …

Background: During the last few years an increasing number of poly (ADP-ribose)
polymerase (PARP) inhibitors have been appearing in the context of cancer therapy. This is …

Pharmacology is focused on studying the effects of endogenous agents and xenobiotics on
tissue and organ function. Analysis of the concentration/response relationship is the …

BRCA1/2 mutations are the most commonly identified germ line gene mutations in patients
with hereditary breast cancer. These proteins have many critical cellular functions, including …

Purpose: Targeting the poly (ADP-ribose) polymerase (PARP) pathway for cancer treatment
has been an active area of pre-clinical and clinical research. We aimed to determine …

Abstract “Translational research”(TR) has the main aim of transferring the results of
preclinical research into clinical practice and includes the study of the biology of the disease …

Phase 0 trials can provide proof of concept that an agent modulates its intended target
without exposing patients to the drug-tolerability testing that precedes efficacy evaluation …

Commentary to: Immunohistochemical detection of poly (ADP-ribose) polymerase inhibition
by ABT-888 in patients with refractory solid tumors and lymphomas Sherry X. Yang, Shivaani …

2009; 27 (16): 2705–2711. 2. Kinders RJ, Hollingshead M, Khin S, et al. Preclinical
modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP …

Despite important recent advances in biomedical research, such as the sequencing of the
human genome, the arrival of the new millennium marked the beginning of a downturn in the …